These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 35371084)

  • 21. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
    J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
    Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
    Kanani A; Veen T; Søreide K
    Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
    J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
    Borelli B; Antoniotti C; Carullo M; Germani MM; Conca V; Masi G
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Checkpoint inhibitors in colorectal carcinoma: are we entering a new era?].
    Pox C
    Inn Med (Heidelb); 2023 May; 64(5):500-505. PubMed ID: 37039887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
    Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer.
    Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
    Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
    Germani MM; Carullo M; Boccaccino A; Conca V; Masi G
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
    Serpas Higbie V; Rogers J; Hwang H; Qiao W; Xiao L; Dasari A; Mola-Rudd K; Morris VK; Wolff RA; Raghav K; Huey R; Parseghian C; Willis J; Kopetz S; Overman MJ; Johnson B
    Oncologist; 2022 Nov; 27(11):952-957. PubMed ID: 35946836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
    Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.